An Analysis of Readmissions to a Mental Health Court

Mental health courts (MHCs) have emerged as one option to address the needs of people with severe mental illness who enter the criminal justice system. Little is known about defendants having multiple referrals to MHCs or the outcomes of subsequent admissions. This study included a sample of 1,084 defendants referred to municipal MHC. During the 13-year study period, 14.3% of defendants had a second admission, with an estimated probability of readmission of 17.4%. Key factors associated with readmission included being eligible to participate in the court but choosing not to do so, being rearrested during court supervision, and having a negative termination from supervision. Defendants who had a second admission during the study period had poorer outcomes than those with one admission. When defendants are referred for readmission to MHCs, careful assessment is required to ensure that these courts are the best alternative for them

CCBC Choices 2016

CCBC CHOICES is an annual list of recommended books for children and young adults selected by the librarians at the Cooperative Children's Book Center, a library of the School of Education at the University of Wisconsin-Madison. CCBC CHOICES 2016 recommends 259 titles for children and young adults published in 2015. It includes a commentary on the 2015 publishing year, including statistics on the number of books by and about people of color and from First/Native Nations published for children and teens

CCBC Choices 2014

children's literature, young adult literature, multicultural literatureCCBC CHOICES is an annual list of recommended books for children and young adults selected by the librarians at the Cooperative Children's Book Center, a library of the School of Education at the University of Wisconsin-Madison. CCBC CHOICES 2014 recommends 233 titles for children and young adults published in 2013. It includes a commentary on the 2013 publishing year, including statistics on the number of books by and about people of color published for children and teens

CCBC Choices 2017

CCBC CHOICES is an annual list of recommended books for children and young adults selected by the librarians at the Cooperative Children's Book Center, a library of the School of Education at the University of Wisconsin-Madison. CCBC CHOICES 2017 recommends 246 titles for children and young adults published in 2016. It includes a commentary on the 2016 publishing year, including statistics on the number of books by and about people of color and from First/Native Nations published for children and teens

CCBC Choices 2018

CCBC CHOICES is an annual list of recommended books for children and young adults selected by the librarians at the Cooperative Children's Book Center, a library of the School of Education at the University of Wisconsin-Madison. CCBC CHOICES 2018 recommends 245 titles for children and young adults published in 2017. It includes a commentary on the 2017 publishing year, including statistics on the number of books by and about people of color and from First/Native Nations received by the CCBC in 2017

Implementation of epic beaker anatomic pathology at an academic medical center

Background: Beaker is a relatively new laboratory information system (LIS) offered by Epic Systems Corporation as part of its suite of health-care software and bundled with its electronic medical record, EpicCare. It is divided into two modules, Beaker anatomic pathology (Beaker AP) and Beaker Clinical Pathology. In this report, we describe our experience implementing Beaker AP version 2014 at an academic medical center with a go-live date of October 2015. Methods: This report covers preimplementation preparations and challenges beginning in September 2014, issues discovered soon after go-live in October 2015, and some post go-live optimizations using data from meetings, debriefings, and the project closure document. Results: We share specific issues that we encountered during implementation, including difficulties with the proposed frozen section workflow, developing a shared specimen source dictionary, and implementation of the standard Beaker workflow in large institution with trainees. We share specific strategies that we used to overcome these issues for a successful Beaker AP implementation. Several areas of the laboratory-required adaptation of the default Beaker build parameters to meet the needs of the workflow in a busy academic medical center. In a few areas, our laboratory was unable to use the Beaker functionality to support our workflow, and we have continued to use paper or have altered our workflow. In spite of several difficulties that required creative solutions before go-live, the implementation has been successful based on satisfaction surveys completed by pathologists and others who use the software. However, optimization of Beaker workflows has continued to be an ongoing process after go-live to the present time. Conclusions: The Beaker AP LIS can be successfully implemented at an academic medical center but requires significant forethought, creative adaptation, and continued shared management of the ongoing product by institutional and departmental information technology staff as well as laboratory managers to meet the needs of the laboratory

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refractory CD30-positive lymphomas. PATIENTS AND METHODS: In this multinational, open-label, phase II study, the efficacy and safety of brentuximab vedotin were evaluated in patients with relapsed or refractory Hodgkin's lymphoma (HL) after autologous stem-cell transplantation (auto-SCT). Patients had histologically documented CD30-positive HL by central pathology review. A total of 102 patients were treated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks. In the absence of disease progression or prohibitive toxicity, patients received a maximum of 16 cycles. The primary end point was the overall objective response rate (ORR) determined by an independent radiology review facility. RESULTS: The ORR was 75% with complete remission (CR) in 34% of patients. The median progression-free survival time for all patients was 5.6 months, and the median duration of response for those in CR was 20.5 months. After a median observation time of more than 1.5 years, 31 patients were alive and free of documented progressive disease. The most common treatment-related adverse events were peripheral sensory neuropathy, nausea, fatigue, neutropenia, and diarrhea. CONCLUSION: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy